Topical Oxybutynin 3% Gel versus Aluminum Chloride 15% Lotion in Treatment of Primary Focal Hyperhidrosis

Amany  El-Agamy El-Samadony; Doaa Salah Hegab; Gamal  Mohamed El Maghraby; Iman  Hamed El-Maadawy

doi:10.5826/dpc.1303a192

Topical Oxybutynin 3% Gel versus Aluminum Chloride 15% Lotion in Treatment of Primary Focal Hyperhidrosis

Authors

Amany El-Agamy El-Samadony Faculty of Medicine, Dermatology and Venereology Department, Tanta University, Tanta, Egypt
Doaa Salah Hegab Faculty of Medicine, Dermatology and Venereology Department, Tanta University, Tanta, Egypt
Gamal Mohamed El Maghraby Faculty of Pharmacy, Pharmaceutical Technology Department, Tanta University, Tanta, Egypt
Iman Hamed El-Maadawy Faculty of Medicine, Dermatology and Venereology Department, Tanta University, Tanta, Egypt

Keywords:

Hyperhidrosis, Oxybutinin, Aluminum chloride, Therapy, Topical

Abstract

Introduction: Hyperhidrosis is excessive sweating beyond thermoregulatory needs. It is a potentially disabling condition with challenging management. Aluminum chloride is the established topical treatment; however, response remains unsatisfactory. Oxybutynin is an anticholinergic drug that stands as a therapeutic chance for hyperhidrosis.

Objectives: comparing the efficacy of topical oxybutynin 3% gel versus aluminum chloride 15% lotion in treatment of primary focal hyperhidrosis.

Methods: Forty patients with hyperhidrosis were randomly distributed into 2 equal groups treated by either topical oxybutynin 3% gel or topical aluminum chloride 15% lotion once daily night application for 4 weeks (both groups). Evaluation was done at 2 and 4 weeks of treatment and after 1 month of the end of treatment for follow up by Minor iodine starch test, hyperhidrosis disease severity scale (HDSS) and dermatology life quality index (DLQI).

Results: Both treatment modalities were effective with insignificant differences between patients of both groups regarding improvement in Minor iodine starch test and HDSS after 2 weeks of treatment (P = 0.561, 0.33 respectively). Oxybutynin 3% gel yielded significantly better improvement of Minor’s test, HDSS and patient’s quality of life at the end of 4 weeks of treatment with lower recurrence rate than aluminum chloride 15% lotion at 1 month follow up. Minimal adverse effects were noted in both studied groups.

Conclusions: Oxybutynin 3% gel could be considered as a promising treatment modality for hyperhidrosis with higher efficacy than aluminum chloride 15% lotion and lower recurrence rate.

References

Pariser DM, Ballard A. Topical therapies in hyperhidrosis care. Dermatol Clin. 2014;32(4):485-490. DOI: 10.1016/j.det.2014.06.008. PMID: 25152341.

Ricchetti-Masterson K, Symons JM, Aldridge M, et al. Epidemiology of hyperhidrosis in 2 population-based health care databases. J Am Acad Dermatol. 2018;78(2):358-62. DOI: 10.1016/j.jaad.2017.10.004. PMID: 28993234.

Hasimoto EN, Cataneo DC, Reis TAD, Cataneo AJM. Hyperhidrosis: prevalence and impact on quality of life. J Bras Pneumol. 2018;44(4):292-298. DOI: 10.1590/S1806-37562017000000379. PMID: 30066741. PMCID: PMC6326708.

Wade R, Jones-Diette J, Wright K, Layton AM, Woolacott N. Hyperhidrosis quality of life measures: review and patient perspective. J Dermatolog Treat. 2019;30(3):303-308. DOI: 10.1080/09546634.2018.1506080. PMID: 30051732.

Nasir A, Bissonnette R, Maari C, et al. A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis. J Eur Acad Dermatol Venereol. 2018;32(1):145-151. DOI: 10.1111/jdv.14651. PMID: 29055158.

Thianboonsong T, Kanokrungsee S, Paichitrojjana A, Udompataikul M, Kamanamool N, Rojhirunsakool S. Efficacy and tolerability of 20% aluminum sesquichlorohydrate vs 20% aluminum chloride for the treatment of axillary hyperhidrosis: A randomized controlled trial. Dermatol Ther. 2020;33(6):e14354. DOI: 10.1111/dth.14354. PMID: 32990370.

Nguyen NV, Gralla J, Abbott J, Bruckner AL. Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults. Pediatr Dermatol. 2018;35(2):208-212. DOI: 10.1111/pde.13404. PMID: 29334132. PMCID: PMC5867207.

Hexsel D, Rodrigues TC, Soirefmann M, Zechmeister-Prado D. Recommendations for performing and evaluating the results of the minor test according to a sweating intensity visual scale. Dermatol Surg. 2010;36(1):120-122. DOI: 10.1111/j.1524-4725.2009.01364.x. PMID: 19930398.

Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Etiology and clinical work-up. J Am Acad Dermatol. 2019;81(3):657-666. DOI: 10.1016/j.jaad.2018.12.071. PMID: 30710604.

Artzi O, Loizides C, Zur E, Sprecher E. Topical Oxybutynin 10% Gel for the Treatment of Primary Focal Hyperhidrosis: A Randomized Double-blind Placebo-controlled Split Area Study. Acta Derm Venereol. 2017;97(9):1120-4112. DOI: 10.2340/00015555-2731. PMID: 28654131.

Moraites E, Vaughn OA, Hill S. Incidence and prevalence of hyperhidrosis. Dermatol Clin. 2014;32(4):457-465. DOI: 10.1016/j.det.2014.06.006. PMID: 25152338.

Augustin M, Radtke MA, Herberger K, Kornek T, Heigel H, Schaefer I. Prevalence and disease burden of hyperhidrosis in the adult population. Dermatology. 2013;227(1):10-13. DOI: 10.1159/000351292. PMID: 23988406.

Wolosker N, Schvartsman C, Krutman M, et al. Efficacy and quality of life outcomes of oxybutynin for treating palmar hyperhidrosis in children younger than 14 years old. Pediatr Dermatol. 2014;31(1):48-53. DOI: 10.1111/pde.12142. PMID: 23627681.

Arora G, Kassir M, Patil A, et al. Treatment of Axillary hyperhidrosis. J Cosmet Dermatol. 2022;21(1):62-70. DOI: 10.1111/jocd.14378. PMID: 34416078.

Campanati A, Gregoriou S, Kontochristopoulos G, Offidani A. Oxybutynin for the Treatment of Primary Hyperhidrosis: Current State of the Art. Skin Appendage Disord. 2015;1(1):6-13.DOI: 10.1159/000371581. PMID: 27172124. PMCID: PMC4857824.

Hölzle E. Topical pharmacological treatment. Curr Probl Dermatol. 2002;30:30-43. doi: 10.1159/000060693. PMID: 12471696.

Streker M, Reuther T, Hagen L, Kerscher M. Hyperhidrosis plantaris - a randomized, half-side trial for efficacy and safety of an antiperspirant containing different concentrations of aluminium chloride. J Dtsch Dermatol Ges. 2012;10(2):115-119. DOI: 10.1111/j.1610-0387.2011.07750.x. PMID: 21848980.

Goh CL. Aluminum chloride hexahydrate versus palmar hyperhidrosis. Evaporimeter assessment. Int J Dermatol. 1990;29(5):368-370. DOI: 10.1111/j.1365-4362.1990.tb04766.x. PMID: 2361796.

Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Therapeutic options. J Am Acad Dermatol. 2019;81(3):669-680. DOI: 10.1016/j.jaad.2018.11.066. PMID: 30710603.

Grabell DA, Hebert AA. Current and Emerging Medical Therapies for Primary Hyperhidrosis. Dermatol Ther (Heidelb). 2017;7(1):25-36. doi: 10.1007/s13555-016-0148-z. PMID: 27787745. PMCID: PMC5336423.